Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________

FORM 8-K
_____________________
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2019
_____________________
KALEIDO BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
________________________ 

Delaware
 
001-38822
 
47-3048279
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
65 Hayden Avenue
Lexington, MA
02421
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code: (617) 674-9000
Not Applicable
(Former name or former address, if changed since last report)
________________________ 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 Par Value
KLDO
NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨


 




Item 2.02.    Results of Operations and Financial Condition.
On August 1, 2019, Kaleido Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01.    Regulation FD Disclosure
The Company is also furnishing a corporate presentation, attached as Exhibit 99.2 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on August 1, 2019. The corporate presentation will also be available in the investor relations section of the Company’s website at http://kaleido.com.
The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits:
 
Exhibit
No.
 
Description
 
 
99.1
 
99.2
 



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
KALEIDO BIOSCIENCES, INC.
 
 
 
 
Date: August 1, 2019
 
 
 
By:
 
/s/ Alison Lawton
 
 
 
 
 
 
Alison Lawton
 
 
 
 
 
 
Chief Executive Officer, President and Director


Exhibit
Exhibit 99.1
http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=13035218&doc=34    

Kaleido Biosciences Reports Second Quarter 2019 Financial Results
and Provides Corporate Update
LEXINGTON, Mass., August 1, 2019 - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update.
“In the second quarter we made important progress with our pipeline and now have five clinical studies underway with our Microbiome Metabolic Therapy (MMT™) candidates,” said Alison Lawton, President and Chief Executive Officer of Kaleido. “We initiated Kaleido’s first Phase 2 clinical trial with the advancement of KB195 for urea cycle disorders (UCD) under an IND. For our KB174 program, we completed enrollment in a dosing study in healthy subjects and continued to progress our clinical study in patients with cirrhosis. We also advanced a third MMT, KB109, into a clinical study in patients colonized with multi-drug resistant pathogens. We look forward to a number of key milestones expected during the second half of the year, including data from three clinical studies in two different patient populations.”

Recent Highlights
Received approval from regulatory authorities in the United Kingdom and Belgium for the Company’s clinical trial application (CTA) for its Phase 2 clinical trial of KB195 in UCD

Initiated the Phase 2 clinical trial evaluating KB195 in patients with UCD

Initiated a non-IND clinical study of KB109 in patients colonized with multi-drug resistant pathogens

Expanded Kaleido’s Scientific Advisory Board to include six leading experts in microbiology, chemistry and microbiome research across a variety of therapeutic areas:

Laurie H. Glimcher, M.D., President and CEO, Dana-Farber Cancer Institute, Director, Dana-Farber/Harvard Cancer Center, and Richard and Susan Smith Professor of Medicine, Harvard Medical School;

Robert Jenq, M.D., Assistant Professor in the Department of Genomic Medicine, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center;

C. Ronald Kahn, M.D., Head of the Section on Integrative Physiology and Metabolism, Past President & CEO, Joslin Diabetes Center, and Mary K. Iacocca Professor of Medicine, Harvard Medical School;

Laura L. Kiessling, Ph.D., Novartis Professor of Chemistry, Massachusetts Institute of Technology;

Max Nieuwdorp, M.D., Professor of Internal Medicine and endocrinologist, University of Amsterdam’s Faculty of Medicine (AMC-UvA); and

Peter J. Turnbaugh, Ph.D., Associate Professor, Department of Microbiology and Immunology, G.W. Hooper Research Foundation, and Investigator, Chan Zuckerberg Biohub, University of California, San Francisco.

Appointed Jerald Korn as General Counsel and Corporate Secretary


1



Members of Kaleido’s leadership team were featured speakers at the 4th Microbiome Movement - Drug Development Summit held June 26-28, 2019 in Boston

Anticipated Key Milestones
Safety and tolerability data from a non-IND clinical study of KB195 in patients with UCD accepted for presentation at the annual Society for the Study of Inborn Errors of Metabolism Symposium, Sept 3-6, 2019

Data from a non-IND clinical study of KB174 in healthy subjects to explore dosing expected in Q4 2019

Data from a non-IND clinical study of KB174 in patients with well-compensated cirrhosis expected in Q4 2019
Second Quarter 2019 Financial Results
For the second quarter ended June 30, 2019, Kaleido reported a net loss of approximately $24.6 million, or $0.83 per share, basic and diluted, compared to a net loss for the quarter ended June 30, 2018 of $12.3 million, or $2.57 per share, basic and diluted.
Total operating expenses for the quarter ended June 30, 2019 were $25.0 million compared to $12.4 million for the quarter ended June 30, 2018.
Research and development expenses for the quarter ended June 30, 2019 were $18.8 million, compared to $9.1 million for the quarter ended June 30, 2018. The increase in expense for the quarter was driven by an increase in external manufacturing and research costs to support the production of study material used in preclinical studies, human clinical studies, and clinical trials as well as clinical research organizations costs associated with MMT candidates for 2019.
General and administrative expenses were $6.2 million for the quarter ended June 30, 2019, compared to $3.2 million for the quarter ended June 30, 2018. The increase in general and administrative expenses compared to the same quarter last year was driven by increased professional services and employee-related costs as the Company continues to expand its infrastructure to support its growth.
Total operating expenses for the quarter ended June 30, 2019 include non-cash stock-based compensation expense of $2.4 million compared to $0.5 million of non-cash stock-based compensation expense for the quarter ended June 30, 2018.
Cash and cash equivalents were $100.0 million as of June 30, 2019

About Microbiome Metabolic Therapies (MMT)
Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome organ’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted glycans that are orally administered, have limited systemic exposure, and are selectively-metabolized by enzymes in the microbiome.  Kaleido utilizes its human-centric discovery and development platform to study MMTs in microbiome samples from healthy subjects and patients in an ex vivo setting, followed by advancing MMT candidates rapidly into non-Investigational New Drug (non-IND) clinical studies in healthy subjects and patients. These non-IND human clinical studies are conducted under regulations supporting research with food, measuring safety, tolerability and potential markers of effect. For MMT candidates that are further developed as therapeutics, the Company conducts clinical trials under an IND or regulatory equivalent outside the U.S., and in Phase 2 or later development.  



About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential of our MMT candidates, the timing of initiation, completion and reporting of results of our clinical studies and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the breadth of our pipeline of product candidates, the strength of our proprietary product platform, the efficiency of our discovery and development approach, the clinical development and safety profile of our MMT candidates and their therapeutic potential, whether and when, if at all, our MMT candidates will receive approval form the U.S. Food and Drug Administration and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our most recent Quarterly Report on Form 10-Q, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.












Kaleido Biosciences, Inc.
Condensed Consolidated Statement of Operations (unaudited)
(in thousands, except share and per share data)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
 
2019
 
2018
 
2019
 
2018
Operating expenses:
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
18,775

 
$
9,140

 
$
33,957

 
$
16,686

 
 
General and administrative
 
6,181

 
3,210

 
11,614

 
5,880

 
 
Total operating expenses
 
24,956

 
12,350

 
45,571

 
22,566

Loss from Operations
 
(24,956
)
 
(12,350
)
 
(45,571
)
 
(22,566
)
 
 
Other (expense) income
 
317

 
2

 
713

 
(542
)
Net loss
 
$
(24,639
)
 
$
(12,348
)
 
$
(44,858
)
 
$
(23,108
)
Net loss per share attributable to common shareholders—basic and diluted
 
$
(0.83
)
 
$
(2.57
)
 
$
(2.10
)
 
$
(4.81
)
Weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted
 
29,667,221

 
4,811,902

 
21,361,749

 
4,804,541


Kaleido Biosciences, Inc.
Condensed Consolidated Balance Sheet Data (unaudited)
(in thousands)
 
 
 
 
 
 
 
 
 
June 30,
 
December 31,
 
 
 
2019
 
2018
Assets:
 
 
 
 
 
Cash and cash equivalents
 
$
99,958

 
$
76,086

 
Other assets
 
10,039

 
9,239

 
Total assets
 
$
109,997

 
$
85,325

Liabilities and stockholders' (deficit) equity
 
 
 
 
 
Liabilities
 
$
25,371

 
$
28,343

 
Preferred stock
 
-

 
153,226

 
Stockholders' (deficit) equity
 
84,626

 
(96,244)

Total liabilities and stockholders' equity
 
$
109,997

 
$
85,325


Contact
Amy Reilly
617-890-5721
amy.reilly@kaleido.com


kaleidooverviewaugust201
Company Overview AUGUST 2019 | ⓒ 2019 KALEIDO™


 
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated use of our existing cash resources, including proceeds from our initial public offering, the duration for which our existing capital resources will fund our operations, statements regarding the therapeutic potential of our Microbiome Metabolic Therapy (MMT) candidates and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, those related to the planned Phase 2 clinical trial for KB195 for the treatment of UCD, including timeline for initiation, completion and reporting of results, the preclinical and clinical development and safety profile of our MMT candidates and timelines associated with the programs for such MMT candidates, whether and when, if at all, our MMT candidates will receive approval from the U.S. Food and Drug Administration or other applicable regulatory agencies, if any, competition from other biotechnology companies, and other risks identified in our SEC filings, including our final prospectus for our initial public offering, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this presentation represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. 2 | ⓒ 2019 KALEIDO™


 
The 1st Company to Use a Chemistry-Driven Approach to Systematically DRIVE FUNCTIONAL OUTPUTS OF THE MICROBIOME ORGAN Leveraging Human-Centric Discovery and Development to Rapidly Translate the Promise of the Microbiome Into Solutions for Patients 3 | ⓒ 2019 KALEIDO™


 
The Kaleido Opportunity Broad Pipeline Human-Centric Proprietary Faster, More Cost with Large World-Class Discovery & Product Platform Efficient Model Market Leadership Team Development Opportunity Significant Computational Biology and Data Science Capabilities Enable Kaleido to Learn MORE, and Learn FASTER 4 | ⓒ 2019 KALEIDO™


 
Built A World-Class Leadership Team Alison Lawton Former GM, Genzyme Biosurgery, President & Chief Executive Officer COO Aura & OvaScience Josh Brumm Former COO & CFO, Versartis, Chief Operating Officer, Chief Financial Officer EVP Finance, Pharmacyclics & CFO, ZELTIQ Kate Knobil, M.D. Former CMO at GlaxoSmithKline Chief Medical Officer, Head of R&D Johan van Hylckama Vlieg, Ph.D. Former VP for Microbiome & Human Chief Scientific Officer Health Innovation, Chr. Hansen Clare Fisher Former Group VP, Global Head of Transactions Chief Business Officer & Business Development, Shire Jerald Korn, J.D. Former Senior Vice President, Chief Legal and General Counsel & Corporate Secretary Administrative Officer, TESARO Mike Bonney Former CEO, Cubist Pharmaceuticals Executive Chair THERAPEUTIC AREA BREADTH CLINICAL DEVELOPMENT COMPANY BUILDING MANUFACTURING & TECHNOLOGY DEPTH & REGULATORY 5 | ⓒ 2019 KALEIDO™


 
Significant Accomplishments Since Founding IND Cleared, Phase 2 clinical trial initiated 12 non-IND human clinical studies conducted with our Microbiome Metabolic Therapy (MMT™) candidates (7 studies completed and 5 in progress) 1,000+ MMT candidates in our library today 5 current pipeline programs in multiple disease areas 100+ non-provisional applications world-wide in 20+ regions/countries, 8 US patents, 2 EPO patents $75M IPO in February 2019 Founded in 2015 to Create a New Category of Drug and Health Products 6 | ⓒ 2019 KALEIDO™


 
Broad Pipeline in Multiple Disease Areas Non-IND Human Clinical Studies1 Mechanism of Ex Vivo Ex Vivo Healthy PROGRAM Target Action Screening Testing Volunteers Patients IND2 Phase 13 Phase 2 Phase 3 Hyperammonemia: Urea Ammonia Cycle Disorders (KB195) Hyperammonemia: Hepatic Encephalopathy Ammonia (KB174 or KB195) Infections Caused MDR by Multi-Drug Resistant Pathogens Bacteria (KB109) Potential to generate 1-2 Phase 2 ready Atherosclerotic programs per year TMA Cardiovascular Disease Uremic Chronic Kidney Disease Toxins Mechanism of Action Completed Note(s): Decrease Production of Metabolites 1. In our non-IND human clinical studies, we evaluate the safety, tolerability and markers of effect of our MMT candidates in human subjects. 2. For MMT candidates pursuing a drug development pathway an IND will be filed; for those that we elect to continue on a non-drug development In Progress pathway, INDs will not be required. Advantage/Disadvantage Certain Species 3. Based on feedback from the FDA and clearance of our IND for KB195 in UCD, we believe we may be able to advance other MMT candidates directly Not Required into Phase 2. 7 | ⓒ 2019 KALEIDO™


 
The Microbiome Organ Has the Potential to Address a Broad Range of Diseases The Microbiome is Implicated in Numerous Conditions • NASH/NAFLD Metabolic Indigenous Bacteria from Gut • Chronic Kidney Disease Microbiota Regulate Host Serotonin Gut Microbiota Regulate Motor Health Biosynthesis Deficits and Neuroinflammation • Metabolic Syndrome in a Model of Parkinson’s Disease Nitrogen • Urea Cycle Disorders • Hepatic Encephalopathy Anticancer immunotherapy The severity of NAFLD is associated with gut Metabolism by CTLA-4 blockade relies on the dysbiosis and shift in the metabolic function of the gut microbiota gut microbiota • MDR Pathogens Gut bacteria from multiple sclerosis Microbial patients modulate human T cells and • Immune homeostasis exacerbate symptoms in mouse models Ecology • GvHD Microbiota Modulate Behavioral and • Oncology Physiological Abnormalities Associated Human nutrition, the gut Immune with Neurodevelopment microbiome and the immune • IBD Disorders system Modulators • Primary Sclerosing Cholangitis Gut microbiome modulates response to • Autism Spectrum anti-PD-1 immunotherapy in melanoma patients CNS • Multiple Sclerosis • Parkinson’s Disease An obesity-associated gut microbiome with increased capacity for energy harvest 8 | ⓒ 2019 KALEIDO™Glycans Are Known to Drive Metabolic Shifts that Have an Impact on Host Physiology


 
We’re Leveraging 10 Years of Scientific Insights and Knowledge Growing Body of Research Powerful Enabling Tools Are Available $115M Human Microbiome Project launched More microbes than 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 human cells NUMBER Microbiome OF PAPERS Koch’s postulates structure revealed Discovery • Computational Capabilities • Shallow Shotgun Sequencing of microbes • Automation & Miniaturization • 16S RNA Sequencing 1890 1980s 1990s 2000s 2010s • Rapid, human-relevant screening • Metabolomics Now Is the Time to Develop Targeted Therapies for the Microbiome Organ 9 | ⓒ 2019 KALEIDO™


 
We Have a Unique and More Evolved Approach FOCUS Functions Drive of the Existing Bacteria Microbiome Add Bacteria Subtract Bacteria Microbiome Metabolic Therapies, or MMTs (i.e. targeted glycans) “Bugs as drugs” (e.g. fecal microbiota transplants, Composition “Kill the bugs” bacterial therapy) of the (e.g. Antibiotics) Microbiome KNOWLEDGE OVER TIME Unique Chemistries that Can Drive the Functional Output of the Microbiome 10 | ⓒ 2019 KALEIDO™


 
Our Microbiome Metabolic Therapies (MMTs) Enable Human-Centric Discovery and Development CHARACTERISTICS ADVANTAGES Drivers of gut metabolism, long history of Initial MMTs are targeted glycans safe human consumption Ability to advance rapidly into the clinic; Related to a class of compounds that is flexibility to develop as therapeutics, food Generally Recognized As Safe (GRAS) or medical food Potentially minimizes off-target Limited systemic exposure biological effects Highly soluble Can be orally administered Novel and proprietary Robust IP portfolio 11 | ⓒ 2019 KALEIDO™


 
Human-Centric Discovery & Development Platform Human Data Drives Learning 1 and MMT 3 Optimization EX VIVO SCREENING RAPID IN HEALTHY ADVANCEMENT INTO MICROBIOME SAMPLES NON-IND HUMAN CLINICAL STUDIES Healthy & Patients Volunteers 2 MMT DECISION POINT • File IND and Proceed to Phase 2 EX VIVO TESTING • Pursue Non-Drug Development IN PATIENT Pathway/Commercialization MICROBIOME SAMPLES Data Collected at Every Stage to Leverage Computational Capability 12 | ⓒ 2019 KALEIDO™


 
Faster, More Cost Efficient Model Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Kaleido’s Discovery IND Start 1 Discovery Non-IND Human Clinical Studies and Development 1 Year 2 Years Phase 2/3 <3 Years Study of Traditional Pharmaceutical Discovery, Preclinical IND Phase 1 Start R&D2 ~5 Years ~1.5 Years Phase 2 5-7 Years Kaleido IND1 Traditional IND Start Phase 2/3 Start Phase 1 ✓ Discovery (human ex vivo) ✓ Dose-response ✓ Discovery Data ✓ Abbreviated preclinical data ✓ Biomarkers may also ✓ Animal Data ✓ Scale for Phase 2 be a surrogate for ✓ Scale to Phase 1 efficacy ✓ Human clinical safety, tolerability Note(s): 1. To date with respect to KB195, which we have decided to develop as a drug candidate 2. DiMasi, Joseph, et. al: Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, 2016, 47, 20-23. 13 | ⓒ 2019 KALEIDO™


 
MMTs Work Through One or More Mechanisms of Action DECREASE ADVANTAGE or DISADVANTAGE Production of Metabolites Certain Species in the Microbiome Community Ammonia MDR Pathogens Hyperammonemia: Urea Cycle Disorders Liver Transplant Patients Hepatic Encephalopathy Hematopoietic Stem Cell Transplantation Patients TMA Atherosclerotic Cardiovascular Disease Uremic Toxins INCREASE Chronic Kidney Disease Production of Metabolites Short Chain Fatty Acids 14 | ⓒ 2019 KALEIDO™


 
Broad Pipeline in Multiple Disease Areas Non-IND Human Clinical Studies1 Mechanism of Ex Vivo Ex Vivo Healthy PROGRAM Target Action Screening Testing Volunteers Patients IND2 Phase 13 Phase 2 Phase 3 Hyperammonemia: Urea Ammonia Cycle Disorders (KB195) Hyperammonemia: Hepatic Encephalopathy Ammonia (KB174 or KB195) Infections Caused MDR by Multi-Drug Resistant Pathogens Bacteria (KB109) Atherosclerotic TMA Cardiovascular Disease Uremic Chronic Kidney Disease Toxins Mechanism of Action Completed Note(s): Decrease Production of Metabolites 1. In our non-IND human clinical studies, we evaluate the safety, tolerability and markers of effect of our MMT candidates in human subjects. 2. For MMT candidates pursuing a drug development pathway an IND will be filed; for those that we elect to continue on a non-drug development In Progress pathway, INDs will not be required. Advantage/Disadvantage Certain Species 3. Based on feedback from the FDA and clearance of our IND for KB195 in UCD, we believe we may be able to advance other MMT candidates directly Not Required into Phase 2. 15 | ⓒ 2019 KALEIDO™


 
The Hyperammonemia Opportunity LIVER Main Site of Ammonia Clearance GUT BRAIN Ammonia Main Site of Production Ammonia Toxicity KB195 KB174 / KB195 Urea Cycle Disorders (UCD) Hepatic Encephalopathy (HE) • Neuropsychiatric abnormalities in patients with liver dysfunction • ~500,000 patients in U.S., many have not been diagnosed • Inability to convert ammonia due to inborn urea cycle defects • Two current approved treatments for Overt HE (OHE) • Orphan disease with ~3,000 patients in U.S. • High Unmet Medical Need • High unmet medical need despite available treatments • No current approved treatment for Minimal HE (MHE) • Reduce the Risk of Life-Threatening Crises • Reduce OHE episodes and infection risk • More tolerable therapy POTENTIAL CLINICAL ENDPOINTS: POTENTIAL CLINICAL ENDPOINTS: • Reduction in serum ammonia 24-hour area under the curve • Time to first breakthrough OHE episode Sources: Batshaw, M. L., et. al. (2014). A longitudinal study of urea cycle disorders, Molecular Genetics and Metabolism, 113(0), 127-130; Montgomery, J. Y., & Bajaj, J. S. (2011). Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy, Current Gastroenterology Reports, 13, 26-33; Company reports 16 | ⓒ 2019 KALEIDO™


 
Ex Vivo Screening & Testing: KB195 Reduced Ammonia in Healthy & Patient Microbiomes Ability to Screen Many MMTs 2 KB195 in UCD Patients 1 Across Our Compound Library for Ability to Reduce Ammonia Reduced Ammonia in All Microbiome Samples Reduced Ammonia by > 50% in 10 Out of 12 Samples Control KB195 Reduced Ammonia by 97%, Compared to Control (water) Ammonia Ammonia Levels Normalized to Control KB195 Ammonia Ammonia Reduction Relative to Control (%) Compound 17 | ⓒ 2019 KALEIDO™


 
KB195 Non-IND Clinical Study in Healthy Subjects KB195 Observed to Have A Significant 3 Effect on Ammonia Reduction • Randomized, controlled, double-blind study in healthy subjects on a high protein diet n=11 • KB195 Significantly Lowered Nitrogen n=12 15 Lactulose − 40.5% Decrease in Urinary N Excretion n=12 ~20% Compared to Negative Control (p=0.0126) reduction1 N Excreted; % Change from Baseline Change % Excreted; N 15 Urine Urine Negative KB195 Comparator control glycan2 Results from 72 g/day dose Note(s): 1. De Preter V. et al., Alimentary Pharmacology & Therapeutics 23, 963-974 (2006) 18 | ⓒ 2019 KALEIDO™ 2. The study also included an additional comparator glycan arm. Operational challenges resulted in interruptions in the dosing schedule and as such, the incomplete comparator glycan arm data are not reported here.


 
KB195 Non-IND Clinical Study in Healthy Subjects KB195 Observed to Have A Significant Fewer Subjects Receiving KB195 3 3 Effect on Ammonia Reduction Reported Diarrhea Negative control 10 KB195 Comparator glycan n=11 6 n=12 Lactulose 4 n=12 ~20% 4 4 reduction1 3 3 N Excreted; % Change from Baseline Change % Excreted; N 15 Urine Urine 1 1 1 1 1 Negative KB195 Comparator 18g/day 36g/day 54g/day 72g/day control glycan2 Dosing Period Results from 72 g/day dose Note(s): 1. De Preter V. et al., Alimentary Pharmacology & Therapeutics 23, 963-974 (2006) 2. The study also included an additional comparator glycan arm. Operational challenges resulted in interruptions 19 | ⓒ 2019 KALEIDO™ in the dosing schedule and as such, the incomplete comparator glycan arm data are not reported here. 3. Based on Bristol Stool Score


 
KB195 in UCD Clinical Program Non-IND patient clinical study • Safety/tolerability of KB195 in ~5 pts with well-controlled UCD Safety & tolerability data expected • Impact on ammonia measured by nitrogen metabolism in blood and urine in Q3’19 UCD Phase 2 open label clinical trial Data expected mid-2020 • ~24 evaluable patients inadequately controlled on standard of care • 8-week treatment period; dose escalated from 9g (BID) to 36g (BID) • Evaluating ammonia levels, including change from baseline in plasma ammonia 24-hour AUC and fasting plasma ammonia • Safety and tolerability Planned open label extension Long term safety & efficacy 1H 2019 2H 1H 2020 2H 2021 20 | ⓒ 2019 KALEIDO™


 
HE Program Advanced into Non-IND Clinical Studies 2 KB195 in Hepatically 3 Initiated two non-IND clinical studies of KB174 Impaired Patients with data expected in Q4’19 Reduced Ammonia in 18 of 19 Microbiome Samples Outperformed Lactulose in Reducing Ammonia KB174 chosen as lead based on ability to reduce Levels in 14 of 19 Samples ammonia and potential impact on infection rates Non-IND study in patients with cirrhosis • Evaluate KB174 compared to a negative control, in adult patients with well-compensated cirrhosis, including: • Nitrogen metabolism • Safety and tolerability Non-IND study in healthy volunteers to explore dosing • Assess various dosing levels of KB174 in healthy subjects evaluating: Ammonia Ammonia Reduction Relative to Control (%) • Nitrogen metabolism • Safety and tolerability 21 | ⓒ 2019 KALEIDO™


 
KB109 in Multi-Drug Resistant Pathogens, a Growing Public Health Threat 1 Ex Vivo Screening 2 Ex Vivo Testing 3 Our MMTs Observed to KB109 Observed to Reduce Reduce Pathogens Pathogens by a Median of 45% Relative to Control • Initiated Non-IND clinical in 10 of 13 Samples study of KB109 in patients colonized with multi-drug resistant pathogens (data expected in 1H’20) − ~64 patients evaluating decolonization, safety and tolerability % % Pathogen Control (%) Pathogen Pathogen Reduction Relative to Hours Microbiome Samples from 13 ICU Patients 22 | ⓒ 2019 KALEIDO™


 
MMT Program for Reduction of TMA in Atherosclerotic Cardiovascular Disease 1 Our top MMTs reduced TMA by >90% in 2 • Two lead MMTs identified in ex vivo testing Ex Vivo Screening Compared To Control • Mechanistic work planned Control 3 • Initiation of non-IND clinical study planned by YE 2020 23 | ⓒ 2019 KALEIDO™


 
Lead Programs in Hyperammonemia Demonstrate the Power of Our Proprietary Product Platform REGULATORY AGENCY FEEDBACK ON UCD • IND cleared in U.S.; KB195 is novel and unique Hyperammonemia • CTAs approved in UK & Belgium Pathologies that Result in an Excess of Ammonia in the Blood CLINICAL • Reduced ammonia levels in ex vivo testing of patient microbiome samples Decrease Production of • First Non-IND Human Clinical Study Ammonia − Lowered Net Ammonia Production1 − Observed Ammonia Reductions Across Heterogeneous Microbiomes • Non-IND clinical study in UCD patients is ongoing • Phase 2 clinical trial initiated SPEED & COST EFFICIENCY VALIDATED • Two MMTs advancing in two hyperammonemia indications Significant Unmet Medical Need • Phase 2 clinical trial initiation ~24 months after first ex vivo screen Urea Cycle Disorders (UCD) Hepatic Encephalopathy (HE) VALIDATED MODEL APPLICABLE ACROSS PIPELINE Note(s): 1. As evidenced by lowered urinary15N excretion in the non-IND clinical study of KB195 in healthy subjects 24 | ⓒ 2019 KALEIDO™


 
Manufacturing is a Core Strategic Advantage Proprietary Methods Standard Small Molecule Unit Operations Scalable and Transferable Internal Manufacturing 3rd Party Manufacturers Production for ex vivo, toxicology, Large scale production for clinical trials and future and human clinical studies commercial supply (Thermo Fisher Scientific) Efficient and scalable process Internal capability to manufacture 12 MMTs per year; potential to double by early 2020 Completed tech transfer to Thermo Fisher in ~6 months, scaled to 1,000 kg with capability to increase by >40X 4 metric tons of KB195 manufactured for Phase 2 trial and toxicology 25 | ⓒ 2019 KALEIDO™


 
Robust Global IP Portfolio 8 U.S. Patents + 2 EPO Patents: • Glycan pharmaceutical compositions (Europe) • Methods to reduce ammonia (U.S.) • Methods to treat diarrhea (U.S.) • Methods to treat dysbiosis (U.S.) • Catalyst compositions (U.S. and Europe) 100+ Non-Provisional Applications Pending, Worldwide in 20+ Regions/Countries • Glycan compositions • Methods to treat pathogen colonization • Methods to treat immune imbalances (e.g. cancer) • Methods to modulate short chain fatty acids • Methods of making glycans Continued IP Expansion by Filing Patent Applications Directed to Pharmaceutical Compositions, Methods of Treatment and Methods of Manufacture 26 | ⓒ 2019 KALEIDO™


 
Key Milestones Data expected Non-IND clinical study in patients UCD Phase 2 clinical trial Non-IND clinical study in patients with cirrhosis HE Non-IND clinical study in healthy volunteers to explore dosing Ready to initiate Phase 2 trial Infections Caused Non-IND clinical study by MDR Bacteria TMA Non-IND clinical study Discovery engines to drive new MMTs for add’l non-IND clinical studies Platform and to generate 1-2 Phase 2 ready programs 1H 2019 2H 1H 2020 2H 2021+ 27 | ⓒ 2019 KALEIDO™


 
The Kaleido Opportunity PLATFORM HUMAN-CENTRIC MODEL PIPELINE TEAM Multiple indications Extensive experience, Enables rapid and MOAs targeting including company Expanding number of advancement of unmet patient needs Demonstrated speed building, product proprietary MMTs, IP, broad portfolio of in significant markets; and cost efficiency to development and computational MMTs by learning non-IND human the clinic manufacturing across capabilities more and faster from clinical studies many technologies human data completed and and therapeutic areas ongoing 28 | ⓒ 2019 KALEIDO™


 
29 | ⓒ 2019 KALEIDO™


 
Financial Overview Cash and Cash Equivalents $100.0M (as of 6/30/19) Operating Expenses (1) $22.6M (for quarter ended 6/30/19) Debt $15.0M (as of 6/30/19) Note(s): 1. Excludes stock-based compensation 30 | ⓒ 2019 KALEIDO™